MISX
MDMG
, Last price
RUB
Name
MD Medical Group Investments PLC
Chart & performance
P/E
—
P/S
—
EPS
130.70
Vol. 1Y
—
Shs. 5Y
—
Rev. 5Y
7.33%
Div Yld LY
—
Div Yld TTM
—
Revenues
33.12b
+19.87%
Net income
9.93b
+30.16%
CFO
11.06b
+17.98%
Dividend
Oct 19, 202638 RUB/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
MD Medical Group Investments Plc, functioning as an investment holding company, specializes in the provision of healthcare services across Russia, primarily targeting women and children. The group's comprehensive medical offerings encompass core specialties such as obstetrics, gynaecology, fertility and IVF treatments, and pediatrics. Beyond these, it extends to a wide spectrum of specialized services, including diagnostics, urology, radiology, surgery, traumatology, rehabilitation, cardiology, oncology, and endovascular procedures, alongside various laboratory examinations. Furthermore, the company engages in pharmaceutical retail and offers assistance services. As of March 28, 2022, its operational footprint was substantial, managing a network of 47 healthcare facilities. This network includes 8 hospitals and 39 outpatient clinics, strategically located across 27 cities and 25 regions. Established in 2006, the company maintains its headquarters in Nicosia, Cyprus, and operates as a subsidiary of MD Medical Holding Limited.
Key people
Vladimir Mekler
Non-Executive Chairman of the Board · since 2016
Vadim Vlasov
Deputy Chief Executive Officer · since 2019
Yulia Kutakova
Medical Director · since 2012
Tatiana Lukina
Non-Executive Independent Director · since 2019
Tony Denis Maher
Non-Executive Independent Director · since 2019
Headquarters & legal address
DIMITRIOU KARATASOU, 15
ANASTASIO BUILDING, FLOOR 6, FLAT 601, STROVOLOS
NICOSIA, 01 2024
CY
ANASTASIO BUILDING, FLOOR 6, FLAT 601, STROVOLOS
NICOSIA, 01 2024
CY
Previous name
MD MEDICAL GROUP INVESTMENTS LTD
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT |